Survival After Relapse of Medulloblastoma. - PubMed - NCBI
ثبت نشده
چکیده
Survival after recurrence of medulloblastoma has not been reported in an unselected cohort of patients in the contemporary era. We reviewed 55 patients diagnosed with medulloblastoma between 2000 and 2010, and treated at Seattle Children's Hospital to evaluate patterns of relapse treatment and survival. Fourteen of 47 patients (30%) over the age of 3 experienced recurrent or progressive medulloblastoma after standard therapy. The median time from diagnosis to recurrence was 18.0 months (range, 3.6 to 62.6 mo), and site of recurrence was metastatic in 86%. The median survival after relapse was 10.3 months (range, 1.3 to 80.5 mo); 3-year survival after relapse was 18%. There were trend associations between longer survival and having received additional chemotherapy (median survival 12.8 vs. 1.3 mo, P=0.16) and radiation therapy (15.4 vs. 5.9 mo, P=0.20). Isolated local relapse was significantly associated with shorter survival (1.3 vs. 12.8 mo, P=0.009). Recurrence of medulloblastoma is more likely to be metastatic than reported in previous eras. Within the limits of our small sample, our data suggest a potential survival benefit from retreatment with cytotoxic chemotherapy and radiation even in heavily pretreated patients. This report serves as a baseline against which to evaluate novel therapy combinations. PMID: 26907655 DOI: 10.1097/MPH.0000000000000547 [PubMed in process] PubMed Commons 0 comments Format: Abstract 1 Author information LinkOut more resources Full text links Survival After Relapse of Medulloblastoma. PubMed NCBI http://www.ncbi.nlm.nih.gov/pubmed/26907655?dopt=Abstract 1 di 1 06/07/2016 10.19
منابع مشابه
Insights into cerebellar development and medulloblastoma. - PubMed - NCBI
Cerebellar development is an extensive process that begins during early embryonic stages and persists more than one year after birth in human. Therefore, the cerebellum is susceptible to acquire various developmental abnormalities leading to numerous diseases such as medulloblastoma, the most common pediatric malignant brain tumor. One third of the patients with medulloblastoma are incurable an...
متن کاملSurvival after recurrence of medulloblastoma in the contemporary era.
2068 Background: Greater than 70% of patients diagnosed with medulloblastoma today are cured. However, salvage therapy after recurrence remains widely varied. Survival after recurrence of medulloblastoma has not been reported in an unselected cohort of patients in the contemporary era. METHODS With approval of the Institutional Review Board, medical records were reviewed for 55 patients diagn...
متن کاملSurvival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961.
The purpose of the trial was to determine the survival and incidence of secondary tumors in children with medulloblastoma receiving radiotherapy plus chemotherapy. Three hundred seventy-nine eligible patients with nondisseminated medulloblastoma between the ages of 3 and 21 years were treated with 2340 cGy of craniospinal and 5580 cGy of posterior fossa irradiation. Patients were randomized bet...
متن کاملThe hallmarks of castration-resistant prostate cancers. - PubMed - NCBI
Prostate cancer has become a real public health issue in industrialized countries, mainly due to patients' relapse by castration-refractory disease after androgen ablation. Castration-resistant prostate cancer is an incurable and highly aggressive terminal stage of prostate cancer, seriously jeopardizing the patient's quality of life and lifespan. The management of castration-resistant prostate...
متن کامل